Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vectus BiosystemsASX:VBS +9.38%15 3-Year RORE % is -14.91 as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 1,291 Biotechnology companies, Vectus Biosystems ranks worse than 53.68% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Vectus Biosystems's 3-Year RORE % for the quarter that ended in Dec. 2025 was -14.91%.
The industry rank for Vectus Biosystems's 3-Year RORE % or its related term are showing as below:
ASX:VBS's 3-Year RORE % is ranked worse than 53.68% of 1291
companies
in the Biotechnology industry
Industry Median: -11.44
vs ASX:VBS: -14.91
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Vectus Biosystems 3-Year RORE % Related Terms
Vectus Biosystems 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Vectus Biosystems's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VBS vs VRTX, REGN, ALNY: 3-Year RORE % Comparison
For the Biotechnology subindustry, Vectus Biosystems's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectus Biosystems 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectus Biosystems's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Vectus Biosystems's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Vectus Biosystems (ASX:VBS) has a 3-Year RORE % of -14.91 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vectus Biosystems and its competitors. According to the industry distribution chart, Vectus Biosystems ranks #693 out of 1291 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Vectus Biosystems' 3-Year RORE % too high?
Vectus Biosystems' current 3-Year RORE % is -14.91. Based on the distribution chart, Vectus Biosystems ranks #693 out of 1291 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' 3-Year RORE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #693 out of 1291 companies for 3-Year RORE %. This places Vectus Biosystems in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Vectus Biosystems and its competitors. Vectus Biosystems's current 3-Year RORE % is -14.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current 3-Year RORE % of -14.91. The current 3-Year RORE % is -14.91. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current 3-Year RORE % is -14.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score
Get the complete analysis for ASX:VBS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VBS has been successfully added to your 
